Please note that the ANZCTR website will be unavailable from 12am until 6am (AEST) on Sunday 22nd September 2019. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Retrospectively registered

Titles & IDs
Public title
efficacy of noble metal alloy endotracheal tube in prevention of ventilatory associated pneumonia
Scientific title
efficacy of noble metal alloy endotracheal tube in prevention of ventilatory associated pneumonia
Secondary ID [1] 296761 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ventilatory associate pneumonia. 310644 0
Condition category
Condition code
Infection 309358 309358 0 0
Other infectious diseases
Respiratory 309419 309419 0 0
Other respiratory disorders / diseases

Study type
Description of intervention(s) / exposure
The intervention group received noble metal alloy coated endotracheal tube used in patients admitted in the toxicology critical care, requiring mechanical ventilation, performed either by emergency doctors and critical care doctors.
endotracheal tube is a device used to protect airway in patients unable to maintain their vital signs.
the duration of intubation depends upon the general status (evaluated by research supervision), but the outcomes were evaluates after 5 days of intervention. there is no min or max duration of time for the alloy tube to stay in place
Intervention code [1] 313071 0
Intervention code [2] 313098 0
Treatment: Devices
Comparator / control treatment
The control group was intubated using silicon uncoated endotracheal tube..
Control group

Primary outcome [1] 308314 0
The primary outcome was the ventilatory associated pneumonia appearance, assessed by the presence of pathogenic bacteria in the tracheal tube.
Timepoint [1] 308314 0
Assessment for ventilatory associated pneumonia was performed after 5 days of mechanical ventilation.
Primary outcome [2] 308315 0
we want to identity the spectrum of endotracheal microbiology using local cultures. this is an exploratory outcome.
Timepoint [2] 308315 0
Timepoint: after 5 days post enrollment.
Secondary outcome [1] 354601 0
secondary outcome: the presence of sepsis, using hemoculture.
Timepoint [1] 354601 0
secondary outcome was assess at 5 days after enrollment.

Key inclusion criteria
We included in the study all subjects that needed mechanical ventilation for acute drug poisoning.
Minimum age
19 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
The exclusion criteria were: trauma patients, inter hospital transferred patients, family refusal.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The intubation was performed with numbered containers. each container had either normal endotracheal tube or noble metal alloy tube.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table from a
statistic book
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 21092 0
State/province [1] 21092 0

Funding & Sponsors
Funding source category [1] 301340 0
Self funded/Unfunded
Name [1] 301340 0
not appliable
Address [1] 301340 0
not appliable
Country [1] 301340 0
Primary sponsor type
tincu radu ciprian
tincu radu ciprian
bucharest clinical emergency hospital
8 floreasca way, Bucharest, 014471, district 1, Romania
Secondary sponsor category [1] 301006 0
Name [1] 301006 0
Address [1] 301006 0
Country [1] 301006 0

Ethics approval
Ethics application status
Ethics committee name [1] 302079 0
Hospital Ethics Committee
Ethics committee address [1] 302079 0
8 Floreasca Way Bucharest
Ethics committee country [1] 302079 0
Date submitted for ethics approval [1] 302079 0
Approval date [1] 302079 0
Ethics approval number [1] 302079 0

Brief summary
Background and Goal of study: Ventilator-associated pneumonia (VAP) is an important matter in patients careed in Intensive Care Units, having an increased burden. The noble metal alloy coated endotracheal tubes (ETTs) have been designed to prevent bacterial colonization and to reduce VAP, but their efficacy, benefits and disadvantages available data are still full of controversy. The objective was to determine whether VAP incidence can be influenced using noble metal alloy ETTs in patients admitted for acute drug poisoning requiring mechanical ventilation.
Material and Methods: A randomized conrolled study was conducted in Critical Care Toxicology Unit, in Bucharest Clinical Emergency Hospital. We enrolled all intubated patients for coma due to drug poisoning, considering the profile of the clinic. All patients were assigned to undergo either uncoated ETTs or noble metal alloy-coated ETTs. Primary outcomes were VAP appearance at 5 days and endotracheal microbiology analysis, while sepsis incidence was secondary outcome.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 89054 0
Dr tincu radu ciprian
Address 89054 0
8 floreasca way, Bucharest, District 1, Romania
principal investigator; Radu Ciprian Tincu,
Bucharest Clinical Emergency Hospital
Country 89054 0
Phone 89054 0
Fax 89054 0
Email 89054 0
Contact person for public queries
Name 89055 0
Dr tincu radu ciprian
Address 89055 0
name of the contact person’s work organisation; tincu radu ciprian
8 floreasca way, Bucharest, District 1, Romania
Country 89055 0
Phone 89055 0
Fax 89055 0
Email 89055 0
Contact person for scientific queries
Name 89056 0
Dr tincu radu ciprian
Address 89056 0
8 floreasca way, Bucharest, District 1, Romania
name of the contact person’s work organisation; Radu Ciprian Tincu,
Country 89056 0
Phone 89056 0
Fax 89056 0
Email 89056 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
all of the individual participant data collected during the trial, after deidentification
When will data be available (start and end dates)?
from 15th of January 2019 until 15th April 2019
Available to whom?
Data will be available for researchers in the same area of interest.
Available for what types of analyses?
IPD metaanalyses
How or where can data be obtained?
access subject to approvals by Principal Investigator requirement to sign data access agreement,
What supporting documents are/will be available?
No other documents available
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – plain English summary